Several other analysts have also issued reports on BOLD. Cowen and Company initiated coverage on Audentes Therapeutics in a research note on Monday, August 15th. They issued an outperform rating on the stock. Wedbush initiated coverage on Audentes Therapeutics in a research note on Monday, August 15th. They issued an outperform rating and a $20.00 target price on the stock.
Audentes Therapeutics (NASDAQ:BOLD) opened at 19.25 on Monday. The firm’s 50-day moving average price is $16.04 and its 200 day moving average price is $15.57. The company’s market cap is $418.21 million. Audentes Therapeutics has a 52-week low of $13.06 and a 52-week high of $20.42.
In related news, insider James E. Flynn acquired 400,000 shares of the firm’s stock in a transaction that occurred on Monday, July 25th. The shares were bought at an average cost of $15.00 per share, for a total transaction of $6,000,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Orbimed Advisors Llc acquired 33,334 shares of the firm’s stock in a transaction that occurred on Monday, July 25th. The shares were bought at an average price of $15.00 per share, for a total transaction of $500,010.00. The disclosure for this purchase can be found here.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is a biotechnology company. The Company focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. Its portfolio of product candidates include AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.